Innata Bio
PrivateLast Round
Series A
Mar 26, 2026
Total Funding Raised
$18.6M
Company Overview
Innata Bio is a biotechnology company that develops small molecule modulators to fine-tune the IL-6/gp130 signaling axis for the treatment of inflammatory and fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innata Bio Comparables
Compare Innata Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cytonics Corporation | 73% | |
| Genascence Corporation | 71% | |
| Biosplice Therapeutics | 71% | |
Innata Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 26, 2026 |
Innata Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| United States Department of Defense | Grant |
| National Institutes of Health (NIH) | Grant |
Innata Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Innata Bio's valuation, stock price, and market status.